International Association of Scientists
www.iasnetedu.com

Available online at www.jobiost.com
IJBLS 2023; 2(2):291-294

International Journal of BioLife Sciences

Review paper

CD47 in Myelodysplastic Syndromes: A Deep Dive into Its Role and Therapeutic Implications

Adela Perolla*

Service of Hematology, Department of Internal Medicine, University Hospital Centre "Mother Teresa"

***Received**: 10 October 2023* ***Revised**: 15 October 2023* ***Accepted**: 18 October 2023*

Abstract

Background and Aim: This review focuses on Myelodysplastic Syndromes (MDS), hematological disorders characterized by dysplastic changes in bone marrow cells. The aim is to explore the role of CD47, known as the "don't eat me" signal, in MDS pathophysiology, understanding its impact on immune evasion, disease progression, and its potential as a prognostic marker.

Method: A systematic literature review was conducted, searching PubMed, Medline, and relevant databases for articles on CD47 in MDS. The analysis includes studies on CD47 expression, its association with immune surveillance, and therapeutic interventions such as monoclonal antibodies and combined strategies with hypomethylating agents.

Results: The review consolidates findings, revealing CD47's crucial role in MDS. Aberrant CD47 overexpression allows immune evasion, potentially contributing to disease progression, and correlates with adverse clinical outcomes. CD47 emerges as a prognostic marker, and early-phase clinical trials on CD47 blockade, especially with monoclonal antibodies, show promising results, offering a novel avenue for MDS management.

Conclusion: In conclusion, this review underscores the pivotal role of CD47 in MDS, influencing immune evasion and disease progression. Elevated CD47 expression serves as a potential prognostic marker, and early-phase clinical trials targeting CD47 present a hopeful direction in MDS management, holding promise for improved therapeutic outcomes.

Keywords: *Myelodysplastic Syndromes (MDS), CD47, Phagocytosis, Immune Evasion, Therapeutic Targeting*

***Corresponding author:** Adela Perolla, Service of Hematology, Department of Internal Medicine, University Hospital Centre "Mother Teresa".
E-mail address: adelaperolla19@gmail.com

Introduction

The spectrum of Myelodysplastic Syndromes (MDS) is vast, with some patients remaining asymptomatic for years and others rapidly progressing to acute myeloid leukemia (AML). Understanding the molecular pathways contributing to MDS's progression is paramount for effective therapy. Among the highlighted molecules in recent years, CD47 has become a focal point of interest [1].

Understanding CD47

CD47, a transmembrane protein, is ubiquitously expressed across various cells. Acting as a "don't eat me" signal, it interacts with the signal regulatory protein alpha (SIRPα) found predominantly on macrophages. This interaction sends an inhibitory signal, preventing the cell from undergoing phagocytosis [2].

Overexpression of CD47 in MDS

Several studies have underscored the aberrant overexpression of CD47 in MDS cells compared to their normal counterparts. For instance, a study by Jaiswal et al. (2009) unveiled that CD47 overexpression is a consistent feature across various MDS subtypes, suggesting a role in disease pathogenesis [3].

What does overexpression achieve? It serves dual purposes:

- Immune Evasion: MDS cells with higher CD47 expression are better equipped to escape immune surveillance, allowing them to thrive and expand.
- Disease Progression: Overexpression has been associated with progression to AML, indicating that these cells may have a competitive advantage over those expressing lower CD47 levels [4].

CD47: A Prognostic Tool in MDS

Beyond its mechanistic role in MDS progression, CD47 expression levels could also serve as a prognostic marker. In a pivotal study by Majeti et al. (2009), higher CD47 expression was found to correlate with a poorer prognosis in MDS patients [5], [6]. Such findings could revolutionize how clinicians assess and stratify patients in terms of therapeutic interventions.

Therapeutic Implications: Targeting CD47

The evident role of CD47 in MDS pathogenesis has ignited interest in targeting it for therapeutic purposes. Several strategies have been pursued:

- Monoclonal Antibodies: Monoclonal antibodies against CD47, like Hu5F9-G4, have shown promise in early-phase trials, with some patients showing significant responses [7].
- Combination Therapies: Given the complex interplay of pathways in MDS, a combination approach might be more effective. Preclinical studies suggest that combining CD47 blockade with hypomethylating agents, such as azacitidine, could potentiate therapeutic effects [8].
- Overcoming Resistance: Targeting a single molecule often leads to compensatory mechanisms, causing resistance. Understanding resistance patterns and developing strategies to overcome them is crucial. Some studies suggest that combining CD47 blockade with inhibitors targeting other immune checkpoints could be a viable strategy [9].

Challenges and Future Perspectives

While the prospect of targeting CD47 is promising, it's not devoid of challenges:

- Off-Target Effects: Since CD47 is widely expressed, there's a potential for off-target effects. Ensuring selectivity is paramount for therapeutic success [10].
- Clinical Trial Design: Determining the optimal patient population, treatment duration, and combinations requires carefully designed clinical trials.
- Economic Implications: Developing targeted therapies can be expensive, and the economic implications of introducing such treatments on a larger scale need to be considered.

Conclusion

The intricate landscape of Myelodysplastic Syndromes (MDS) continues to unravel, with CD47 emerging as a pivotal molecule in its pathophysiology. CD47's function as the "don't eat me" signal offers MDS cells a shield against immune-mediated clearance, possibly driving disease progression. Overexpression of CD47 in MDS cells not only offers a glimpse into the disease's underlying mechanisms but also underscores the potential of CD47 as a prognostic marker. Its association with poorer clinical outcomes and disease progression to acute myeloid leukemia (AML) demands attention. Therapeutically, CD47 presents an exciting avenue. Preliminary findings from early-phase clinical trials indicate that targeting CD47, either as monotherapy or in combination with established treatments, holds promise in improving patient outcomes. However, as with many novel therapeutic strategies, challenges persist, particularly regarding off-target effects and the potential for therapeutic resistance. As our understanding deepens and therapeutic modalities evolve, targeting CD47 may usher in a new era in MDS management, bringing hope to patients and adding a valuable tool to the hematologist's arsenal.

Acknowledgment

I would like to express my sincerest appreciation to all the researchers and authors of the studies reviewed in this paper.

Conflict of interests

The author declares that she has no pertinent affiliations or monetary associations with any organizations or entities that have a financial stake in or conflict with the subject matter or materials covered in this manuscript.

Reference

[1]. Nachtkamp K, Kobbe G, Gattermann N, Germing U. Myelodysplastic Syndromes: New Methods of Diagnosis, Prognostication, and Treatment. Dtsch Arztebl Int. 2023;120(12):203-10.
[2]. Oldenborg PA. Role of CD47 in erythroid cells and in autoimmunity. Leuk Lymphoma. 2004;45(7):1319-27.
[3]. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271-85.
[4]. Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer research. 2011;71(4):1374-84.
[5]. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, van Rooijen N, Weissman IL. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286-99.

[6]. Eladl E, Tremblay-LeMay R, Rastgoo N, Musani R, Chen W, Liu A, Chang H. Role of CD47 in hematological malignancies. Journal of Hematology & Oncology. 2020;13(1):1-14.
[7]. Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma. New England Journal of Medicine. 2018;379(18):1711-21.
[8]. Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, Chao M, Weissman IL, Majeti R. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PloS one. 2015;10(9):e0137345.
[9]. Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard, M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer JP, Majeti R, Weissman IL, Takimoto CH, Supan D, Wakelee HA, Aoki R, Pegram MD, Padda SK. First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. Journal of Clinical Oncology. 2019;37(12):946.
[10]. Weiskopf K. Cancer immunotherapy targeting the CD47/SIRPα axis. Eur J Cancer. 2017;76:100-9.